S
60 DEGREES PHARMACEUTICALS, INC.
Period
FY 2025
Revenue
$1.01M
Net Income
$-7.37M
Total Assets
$5.37M
Equity
$3.46M
Shares Out
2.66M
Op. Cash Flow
$-6.85M
Business
60 Degrees Pharmaceuticals is a specialty pharmaceutical company developing therapies for infectious diseases. It markets Arakoda (tafenoquine), a malaria preventative approved by the FDA in 2018 and commercially available since 2019, and is expanding its pipeline to include tafenoquine-based products for tick-borne diseases like babesiosis, fungal infections, and viral diseases including Celgosivir and Australian Chestnut Extract. The company operates primarily in the United States with a subsidiary in Australia holding ex-U.S. sublicensing rights.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Product Revenues net of Discounts and Rebates | 1 | 607,574 | 253,573 | 223,208 | |
| Cost of Revenues | 781,695 | 384,765 | 474,550 | 432,370 | |
| Gross Profit | 223,776 | 222,809 | −220,977 | −209,162 | |
| Research Revenues | 403,624 | 73,771 | — | 288,002 | |
| Net Revenue | 627,400 | 296,580 | −220,977 | — | |
| Research and Development | 2 | 5 | 691,770 | 525,563 | |
| General and Administrative Expenses | 6 | 5 | 4 | 1 | |
| Total Operating Expenses | 8 | 10 | 5 | 2 | |
| Loss from Operations | −8 | −10 | −5 | −2 | |
| Interest Expense | −7,805 | −7,912 | −2 | — | |
| Change in Fair Value of Derivative Liabilities | 266,089 | 2 | — | — | |
| Other Income, net | 131,970 | 101,464 | −83,116 | −43,238 | |
| Total Interest and Other Income (Expense), net | 390,254 | 2 | — | — | |
| Loss from Operations before Provision for Income Taxes | −7 | −8 | −4 | −6 | |
| Provision for Income Taxes (Note 9) | 0 | 0 | 250 | 500 | |
| Net Loss including Noncontrolling Interest | −7 | −8 | −4 | −6 | |
| Net Loss Noncontrolling Interest | −3,167 | −8,556 | −48,098 | 3,936 | |
| Net Loss attributed to 60 Degrees Pharmaceuticals, Inc. | −7 | −8 | −4 | −6 | |
| Unrealized Foreign Currency Translation Gain (Loss) | 7,127 | −90 | 61,853 | — | |
| Total Comprehensive Loss | −7 | −8 | −4 | −6 | |
| Net Loss Noncontrolling Interest | −3,167 | −8,556 | −48,098 | — | |
| Comprehensive Loss attributed to 60 Degrees Pharmaceuticals, Inc. | −7 | −8 | −4 | −6 | |
| Cumulative Dividends on Series A Preferred Stock | −501,056 | −483,301 | −220,714 | — | |
| Net Loss - attributed to common stockholders | −8 | −8 | −4 | −6 | |
| Basic (in Dollars per share) | −11.73 | −74.17 | −59.18 | −2.61 | |
| Diluted (in Dollars per share) | −11.73 | −74.17 | −59.18 | −2.61 | |
| Basic (in Shares) | 670,211 | 113,665 | 66,314 | 2 | |
| Diluted (in Shares) | 670,211 | 113,665 | 66,314 | 2 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | 2 | 2 | 2 | — | — | |
| Accounts Receivable | 509,644 | 486,748 | 231,332 | 45,965 | — | |
| Prepaid and Other Assets | 978,131 | 1 | 4 | — | — | |
| Short-Term Investments | 1 | 2 | — | — | — | |
| Inventory (Note 3) | 656,924 | 442,764 | 466,169 | 518,578 | — | |
| Total Current Assets | 5 | 5 | 7 | 1 | — | |
| Property and Equipment, net (Note 4) | 246,365 | 149,808 | 57,761 | 21,300 | — | |
| Long-Term Prepaid Expense | 0 | 66,176 | 242,647 | — | — | |
| Intangible Assets, net (Note 5) | 224,361 | 157,084 | 227,258 | 164,255 | — | |
| Total Other Assets | 224,361 | 223,260 | 483,422 | — | — | |
| Total Assets | 5 | 6 | 8 | 1 | — | |
| Accounts Payable and Accrued Expenses | 1 | 1 | 506,206 | 758,668 | — | |
| SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 | — | — | — | |
| Derivative Liabilities (Note 8) | 374,741 | 640,830 | 2 | 1 | — | |
| Total Current Liabilities | 2 | 2 | 3 | 24 | — | |
| SBA EIDL (including accrued interest) (Note 7) | 144,003 | 147,119 | — | — | — | |
| Total Long-Term Liabilities | 144,003 | 147,119 | 150,251 | 2 | — | |
| Total Liabilities | 2 | 2 | 3 | 25 | — | |
| Commitments and Contingencies (Note 11) | — | — | — | — | — | |
| Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively (Note 6) | 10 | 10 | 10 | — | — | |
| Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,163,142 and 141,749 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively(1) (Note 6) | 116 | 14 | 10 | 239 | — | |
| Additional Paid-in Capital | 42 | 35 | 27 | 5 | — | |
| Accumulated Other Comprehensive Income | 142,598 | 135,471 | 135,561 | 73,708 | — | |
| Accumulated Deficit | −48 | −41 | −33 | −29 | — | |
| 60P Shareholders Equity: | 3 | 4 | 5 | −24 | — | |
| Noncontrolling Interest | −83,761 | −80,594 | −72,038 | −572,320 | — | |
| Total Shareholders Equity | 3 | 4 | 5 | −24 | −18 | |
| Total Liabilities and Shareholders Equity | 5 | 6 | 8 | 1 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Depreciation | 43,324 | 11,726 | 21,162 | 27,648 | |
| Amortization | 39,548 | 38,502 | 29,157 | 5,118 | |
| Amortization of ROU Asset | 0 | 13,517 | 50,053 | — | |
| Amortization of Capitalized Share-Based Payments | 176,471 | 4 | 994,643 | — | |
| Share-Based Compensation under Equity Incentive Plan | 279,873 | 32,767 | 528,926 | — | |
| Change in Fair Value of Derivative Liabilities | −266,089 | −2 | 37,278 | — | |
| Write-offs of Capitalized Patents | 0 | 108,424 | — | — | |
| Change in Inventory Reserve | 251,677 | 0 | — | — | |
| Accounts Receivable | −22,896 | −255,416 | −185,367 | 100,397 | |
| Prepaid and Other Assets | −19,486 | −39,423 | −522,370 | 24,902 | |
| Inventory | −465,837 | 23,405 | 212,747 | 10,126 | |
| Accounts Payable and Accrued Liabilities | 491,083 | 501,412 | −214,734 | 169,990 | |
| Accrued Interest, net | 11,635 | −23,604 | 1 | 3 | |
| Reduction of Lease Liability | 0 | −13,650 | −50,273 | −46,795 | |
| Net Cash Used in Operating Activities | −7 | −6 | −5 | −1 | |
| Capitalization of Patents | −55,533 | −51,967 | −39,982 | — | |
| Purchases of Fixed Assets | −139,881 | −103,773 | −57,623 | — | |
| Acquisition of Intangibles | −22,670 | −25,374 | −18,283 | −27,070 | |
| Purchase of Short-Term Investments | −1 | −2 | — | — | |
| Maturities of Short-Term Investments | 2 | 0 | — | — | |
| Net Cash Provided by (Used in) Investing Activities | 254,916 | −2 | −115,888 | −60,133 | |
| Net Proceeds from January 2024 Offering | 0 | 2 | — | — | |
| Net Proceeds from January 2025 Offering | 804,346 | 0 | — | — | |
| Net Proceeds from February 2025 Offering | 908,627 | 0 | — | — | |
| Net Proceeds From July 2025 Offering | 4 | 0 | — | — | |
| Shares Withheld for Net Share Settlement of Performance Bonuses | −18,000 | 0 | — | — | |
| Net proceeds from ATM Offering | 458,614 | 2 | — | — | |
| Net proceeds from Private Placement | 0 | 3 | — | — | |
| Proceeds from Exercise of Pre-Funded Warrants | 2,804 | 10,963 | — | — | |
| Net Cash Provided by Financing Activities | 6 | 7 | 6 | 1 | |
| Effect of Exchange Rate Changes on Cash | 7,127 | 499 | 61,853 | — | |
| Change in Cash and Cash Equivalents | −149,288 | −483,132 | 2 | 149,466 | |
| Cash paid During the Year for Interest | 8,772 | 8,772 | 179,117 | 2,193 | |
| Cash paid During the Year for Income Taxes | 0 | 0 | 1,000 | 1,000 | |
| Conversion of Series A Preferred Stock into Common Stock | 0 | 290,601 | 270,460 | — | |
| Capitalized Share-Based Payments to Vendors | 0 | 26,325 | 5 | — | |
| Fair Value of Warrants Issued to Underwriters | 0 | 71,364 | 301,416 | — | |
| Capitalized Patent Costs included in Accounts Payable | 24,292 | 0 | 33,895 | — | |
| Capitalized Website Costs included in Accounts Payable | 4,330 | 0 | — | — | |
| ATM Offering Costs included in Accounts Payable | 53,500 | 0 | — | — | |
| Gross Shares Issued for Annual Performance Bonuses | 121,544 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is 60 DEGREES PHARMACEUTICALS, INC.'s CIK number?
60 DEGREES PHARMACEUTICALS, INC.'s SEC CIK number is 0001946563 (1946563). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find 60 DEGREES PHARMACEUTICALS, INC.'s SEC filings?
All of 60 DEGREES PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.